<?xml version="1.0" encoding="utf-8" standalone="no"?>
<!DOCTYPE file
  SYSTEM 'wikixml.dtd'>
<file type="Article" date="2024-09-24T08:12:23Z" sourceCorpus="COVID-19" filename="69582962" title="ABNCoV2" url="https://en.wikipedia.org/wiki/ABNCoV2">
	<text>
		<segment id="id69582962">ABNCoV2 is a cVLP COVID-19 vaccine candidate developed by Expres2ion Biotechnologies and Adaptvac, outlicensed to Bavarian Nordic.

On 9 August 2021, it was announced that the first round of trials of the vaccine had been finalized with good results among 45 test subjects.

 References 














</segment>
	</text>
</file>
